{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:40:26Z","timestamp":1776148826917,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Catastrophic antiphospholipid syndrome (CAPS) is an uncommon but often fatal manifestation of antiphospholipid syndrome, marked by rapid, diffuse microvascular thrombosis with multiorgan involvement. In practice, the initial clinical picture can be indistinguishable from severe infection or sepsis-associated organ failure, which makes early diagnosis challenging. Early recognition is critical, as delayed intervention is associated with high mortality. We report a case of probable CAPS that presented with splenic infarction and shock in the setting of suspected sepsis. Her condition progressed quickly to multiorgan dysfunction, and antiphospholipid antibody testing repeatedly showed high-titer triple positivity. After probable CAPS was considered, triple therapy (high-dose glucocorticoids, anticoagulation, and therapeutic plasma exchange) was initiated, and she was discharged after clinical stabilization. She was later readmitted with fulminant infection and recurrent CAPS-like manifestations. Anticoagulation and plasma exchange were not restarted, and she died within 72 h, highlighting two contrasting courses under diagnostic uncertainty.<\/jats:p>","DOI":"10.3389\/fmed.2026.1752865","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:40:20Z","timestamp":1776145220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report of a fatal probable catastrophic antiphospholipid syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Sheng-Jie","family":"Hou","sequence":"first","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Xin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanlin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]},{"name":"Department of Emergency Medicine, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]},{"name":"Department of Emergency Medicine, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/ijms25010668","article-title":"Catastrophic antiphospholipid syndrome.","volume":"25","author":"Bitsadze","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14740\/jocmr4154","article-title":"The issue of the antiphospholipid antibody syndrome.","volume":"12","author":"Oliveira","year":"2020","journal-title":"J Clin Med Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e69730","DOI":"10.7759\/cureus.69730","article-title":"Catastrophic antiphospholipid syndrome: a review of current evidence and future management practices.","volume":"16","author":"Okunlola","year":"2024","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients.","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.15903","article-title":"The role of plasma exchange in the management of autoimmune disorders.","volume":"186","author":"Zanatta","year":"2019","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/(sici)1098-1101(1999)14:4<171::aid-jca3>3.0.co;2-5","article-title":"Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy.","volume":"14","author":"Flamholz","year":"1999","journal-title":"J Clin Apher."},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.lpm.2019.10.003","article-title":"Plasma exchange in catastrophic antiphospholipid syndrome.","volume":"48","author":"Rodr\u00edguez-Pint\u00f3","year":"2019","journal-title":"Presse Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria.","volume":"13","author":"Jacobs","year":"2024","journal-title":"Antibodies"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/ard.2005.045443","article-title":"Infectious origin of the antiphospholipid syndrome.","volume":"65","author":"Shoenfeld","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5935\/0103-507x.20140026","article-title":"Antiphospholipid antibodies in critically ill patients.","volume":"26","author":"Vassalo","year":"2014","journal-title":"Rev Bras Ter Intensiva"},{"key":"B13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/life13020350","article-title":"Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines.","volume":"13","author":"Tsantes","year":"2023","journal-title":"Life"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13613-025-01434-2","article-title":"Biomarkers of sepsis-induced coagulopathy: diagnostic insights and potential therapeutic implications.","volume":"15","author":"Curtiaud","year":"2025","journal-title":"Ann Intensive Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2010024","DOI":"10.4084\/MJHID.2010.024","article-title":"Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.","volume":"2","author":"Semeraro","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the ninth special issue.","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.21873\/invivo.13286","article-title":"Therapeutic plasma exchange in catastrophic antiphospholipid syndrome (CAPS): a rare case report and literature review.","volume":"37","author":"Bereanu","year":"2023","journal-title":"In Vivo"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.transci.2018.02.008","article-title":"Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome.","volume":"57","author":"\u00d6zg\u00fcr","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults.","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.clim.2023.109828","article-title":"Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management.","volume":"257","author":"Cole","year":"2023","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1145145","DOI":"10.3389\/fimmu.2023.1145145","article-title":"An update on the biologics for the treatment of antiphospholipid syndrome.","volume":"14","author":"Yun","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry\u201d.","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1752865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:40:21Z","timestamp":1776145221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1752865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":23,"alternative-id":["10.3389\/fmed.2026.1752865"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1752865","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1752865"}}